相关实验视频

Updated: Sep 16, 2025

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood

Published on: January 9, 2018

N型电压通道抗体测试在兰伯特-伊顿肌综合征中缺乏诊断价值

Friederike A Arlt¹, Masoud Majed², Jack Wu¹

¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America.

Journal of neuroimmunology

|July 12, 2025

概括

电压通道N型 (VGCC-N) 抗体测试没有改善兰伯特-伊顿肌综合征 (LEMS) 的诊断. 在LEMS患者中,SOX1-IgG测试是小细胞肺癌的更好的预测.

科学领域:

神经学神经学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

兰伯特-伊顿肌综合征 (LEMS) 诊断依赖于对电压通道抗体 (VGCC) 的血清学检测.
虽然VGCC-P/Q型 (VGCC-PQ) 抗体是已确定的LEMS生物标志物,但VGCC-N型 (VGCC-N) 抗体的实用性尚不清楚.

研究的目的:

在LEMS中评估VGCC-N抗体测试的诊断价值.
为了比较VGCC-N抗体与小细胞肺癌 (SCLC) 的SOX1-IgG在LEMS中的预测值.

主要方法:

从1995年到2021年对LEMS患者 (n=123) 和健康对照 (n=122) 的回顾性横截面研究.
对血清VGCC-PQ,VGCC-N和SOX1抗体的分析.
对抗体测试性能进行统计评估.

主要成果:

在84.6%的LEMS病例中检测到VGCC-PQ抗体.
在20.5%的LEMS病例中发现了VGCC-N抗体,大多数与VGCC-PQ抗体同时发生.
与SOX1-IgG不同的是,VGCC-N抗体阳性没有预测SCLC-LEMS,而SOX1-IgG.

结论:

VGCC-N抗体测试不会提高LEMS诊断的准确性.
与SOX1-IgG.不同的是,VGCC-N抗体对于相关癌症缺乏预测价值.
建议排除VGCC-N抗体测试,因为它具有非特异性关联和较低的阳性预测值.

关键词:

兰伯特-伊顿肌痛性肌痛综合征是什么 N型电压通通道抗体 P/Q型电压通通道抗体在SOX1-IgG中.电压关联通道抗体.

更多相关视频

Acute Dissociation of Lamprey Reticulospinal Axons to Enable Recording from the Release Face Membrane of Individual Functional Presynaptic Terminals

Acute Dissociation of Lamprey Reticulospinal Axons to Enable Recording from the Release Face Membrane of Individual Functional Presynaptic Terminals

Published on: October 1, 2014

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

相关概念视频

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...